The US Food and Drug Administration (FDA) has approved a label expansion for Novartis’s Kisqali (ribociclib), allowing it to ... The label expansion approval was backed by positive data from the ...

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic ... published earlier this year in JAMA Network Open. Nikki Odum, 42, was diagnosed with breast cancer ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

Kisqali is a prescription drug used with other medications to treat certain kinds of breast cancer. Kisqali can cause side effects that range from mild to serious, such as fatigue, hair loss, and ...

Ribociclib 200mg; with letrozole 2.5mg; tabs. Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and play a crucial role in ...

“We continue to transform cancer care with Kisqali, building on its established profile in the metastatic setting and now helping a wide range of people as they strive to stay cancer-free ...

How Do I Take Kisqali? Kisqali is taken as a tablet that you swallow. You take Kisqali once a day for 21 days in a row, and then have 7 days where you do not take Kisqali. This means that in every ...

NATALEE is a global Phase III multi-center, randomized, open-label trial to evaluate the efficacy and safety of Kisqali with ET as an investigational adjuvant treatment versus ET alone in patients ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment ...